Harrow Health
| Formerly | Imprimis Pharmaceuticals ( - Jan 2019) |
|---|---|
| Company type | Public |
| Nasdaq: HROW Russell Microcap Index component | |
| Industry | Pharmaceutical Industry |
| Founded | 2012 |
| Headquarters | Nashville, Tennessee , United States |
Number of locations | 1 (Nashville, TN) |
Key people | |
| Products | Pharmaceuticals |
| Subsidiaries |
|
| Website | www |
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary.